

Niall M Corcoran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9328218/publications.pdf>

Version: 2024-02-01

77
papers

2,901
citations

218381
26
h-index

182168
51
g-index

77
all docs

77
docs citations

77
times ranked

5687
citing authors

#	ARTICLE	IF	CITATIONS
1	A review of simulation training and new 3D computer-generated synthetic organs for robotic surgery education. <i>Journal of Robotic Surgery</i> , 2022, 16, 749-763.	1.0	19
2	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100070.	1.0	10
3	Protocol for CAMUS Delphi Study: A Consensus on Comprehensive Reporting and Grading of Complications After Urological Surgery. <i>European Urology Focus</i> , 2022, 8, 1493-1511.	1.6	9
4	Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer. <i>Cancers</i> , 2022, 14, 166.	1.7	0
5	Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. <i>Prostate</i> , 2022, 82, 993-1002.	1.2	2
6	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. <i>Uro</i> , 2022, 2, 74-92.	0.3	3
7	A Historical Perspective of the Evolution of Laparoscopic Surgeries in Urology. <i>Journal of Endourology</i> , 2022, 36, 1277-1284.	1.1	1
8	Active involvement of nursing staff in reporting and grading complication/intervention events: Protocol and results of the CAMUS Pilot Nurse Delphi Study. <i>BJU Compass</i> , 2022, 3, 466-483.	0.7	2
9	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. <i>BMC Urology</i> , 2021, 21, 18.	0.6	3
10	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. <i>European Journal of Cancer</i> , 2021, 148, 440-450.	1.3	13
11	Loss of <i>SNAI2</i> in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1048-1059.	1.5	9
12	MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1167-1180.	2.0	4
13	Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression. <i>BMC Cancer</i> , 2021, 21, 846.	1.1	3
14	Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer. <i>Value in Health</i> , 2021, 24, 1737-1745.	0.1	4
15	The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade. <i>BJU International</i> , 2021, , .	1.3	2
16	Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. <i>Genome Medicine</i> , 2020, 12, 72.	3.6	35
17	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. <i>Science</i> , 2020, 368, 1127-1131.	6.0	83
18	Use of prostate-specific membrane antigen positron emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. <i>BJU International</i> , 2020, 126, 433-435.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Inferring structural variant cancer cell fraction. Nature Communications, 2020, 11, 730.	5.8	33
20	Prostate cancer cellâ€intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 2020, 21, e50162.	2.0	58
21	Advances in prostate cancer. Australian Journal of General Practice, 2020, 49, 200-205.	0.3	4
22	What Is Oligometastatic Prostate Cancer?. European Urology Focus, 2019, 5, 159-161.	1.6	24
23	Lessons Learned and New Challenges: Re-evaluation of End-User Assessment of a Skills-Based Training Program for Urology Trainees. Journal of Medical Education and Curricular Development, 2019, 6, 238212051983455.	0.7	6
24	Prostatic nerve subtypes independently predict biochemical recurrence in prostate cancer. Journal of Clinical Neuroscience, 2019, 63, 213-219.	0.8	8
25	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. Neurotherapeutics, 2019, 16, 192-202.	2.1	69
26	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. European Urology, 2019, 76, 89-97.	0.9	158
27	Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. Experimental Cell Research, 2019, 374, 353-364.	1.2	31
28	Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation. MethodsX, 2019, 6, 22-34.	0.7	0
29	Developments in oligometastatic hormone-sensitive prostate cancer. World Journal of Urology, 2019, 37, 2549-2555.	1.2	5
30	Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression. BJU International, 2019, 123, 976-984.	1.3	6
31	Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat. Endocrine Connections, 2019, 8, 547-558.	0.8	16
32	Obesity suppresses tumor attributable PSA, affecting risk categorization. Endocrine-Related Cancer, 2018, 25, 561-568.	1.6	5
33	Roboticâ€assisted radical cystectomy with intracorporeal urinary diversion versus open: early Australian experience. ANZ Journal of Surgery, 2018, 88, 1028-1032.	0.3	14
34	Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. Endocrine-Related Cancer, 2018, 25, 569-581.	1.6	19
35	New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2018, 18, 951-957.	0.9	0
36	3D modelling of radical prostatectomy specimens: Developing a method to quantify tumor morphometry for prostate cancer risk prediction. Pathology Research and Practice, 2017, 213, 1523-1529.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. <i>Prostate</i> , 2017, 77, 1416-1423.	1.2	22
38	Routinely reported "equivocal" lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. <i>BJU International</i> , 2017, 119, 567-572.	1.3	15
39	How Subclonal Modeling Is Changing the Metastatic Paradigm. <i>Clinical Cancer Research</i> , 2017, 23, 630-635.	3.2	34
40	Androgen synthesis in prostate cancer: do all roads lead to Rome?. <i>Nature Reviews Urology</i> , 2017, 14, 49-58.	1.9	34
41	Disrupting the Status Quo in Prostate Cancer Diagnosis. <i>European Urology</i> , 2017, 71, 193-194.	0.9	2
42	Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. <i>Oncotarget</i> , 2017, 8, 52237-52255.	0.8	55
43	A Phase IIa Randomized Control Trial of S100B (Sodium Selenate) in Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 223-232.	1.2	53
44	Comparing nodal versus bony metastatic spread using tumour phylogenies. <i>Scientific Reports</i> , 2016, 6, 33918.	1.6	19
45	Stimulation of the Neurovascular Bundle Results in Rhabdosphincter Contraction in a Proportion of Men Undergoing Radical Prostatectomy. <i>Urology</i> , 2016, 87, 133-139.	0.5	9
46	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. <i>Clinical Cancer Research</i> , 2016, 22, 3132-3137.	3.2	28
47	Feasibility for active surveillance in biopsy Gleason 3+4 prostate cancer: an Australian radical prostatectomy cohort. <i>BJU International</i> , 2016, 117, 82-87.	1.3	21
48	High-resolution Map of Somatic Periprostatic Nerves. <i>Urology</i> , 2016, 97, 160-165.	0.5	6
49	Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. <i>Brain</i> , 2016, 139, 1919-1938.	3.7	100
50	The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2016, 42, 56-72.	3.4	432
51	A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. <i>British Journal of Cancer</i> , 2016, 114, 454-462.	2.9	78
52	Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. <i>Oncotarget</i> , 2016, 7, 31384-31392.	0.8	11
53	Prostate cancer multidisciplinary care: improving patient outcomes. <i>Trends in Urology & Men's Health</i> , 2015, 6, 18-20.	0.2	1
54	Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?. <i>Canadian Urological Association Journal</i> , 2015, 9, 252.	0.3	21

#	ARTICLE	IF	CITATIONS
55	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. <i>Nature Communications</i> , 2015, 6, 6605.	5.8	312
56	Bone Turnover Markers and Prostate Cancer: Not Just a Measure of Bone Disease?. <i>European Urology</i> , 2015, 68, 51-52.	0.9	5
57	Preservation of the Neurovascular Bundles Is Associated with Improved Time to Continence After Radical Prostatectomy But Not Long-term Continence Rates: Results of a Systematic Review and Meta-analysis. <i>European Urology</i> , 2015, 68, 692-704.	0.9	144
58	Curated MicroRNAs in Urine and Blood Fail to Validate as Predictive Biomarkers for High-Risk Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e91729.	1.1	43
59	Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Response. <i>Clinical Cancer Research</i> , 2014, 20, 4972-4973.	3.2	1
60	Gene-based urinary biomarkers for bladder cancer: An unfulfilled promise?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 48.e9-48.e17.	0.8	38
61	Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5547-5557.	3.2	43
62	Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer. <i>BJU International</i> , 2013, 111, 921-927.	1.3	17
63	Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. <i>Pathology</i> , 2012, 44, 204-208.	0.3	12
64	Targeted therapy in prostate cancer. <i>Histopathology</i> , 2012, 60, 216-231.	1.6	14
65	Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. <i>Neurobiology of Disease</i> , 2012, 45, 897-901.	2.1	70
66	Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. <i>BJU International</i> , 2012, 109, 660-664.	1.3	66
67	The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. <i>BJU International</i> , 2012, 110, 36-42.	1.3	61
68	Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediate-risk disease. <i>BJU International</i> , 2012, 110, 821-827.	1.3	28
69	Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. <i>Pathology</i> , 2011, 43, 138-142.	0.3	26
70	Lessons learned: end-user assessment of a skills laboratory based training programme for urology trainees. <i>BJU International</i> , 2011, 107, 47-51.	1.3	5
71	Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. <i>BJU International</i> , 2011, 108, E202-E210.	1.3	103
72	Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2010, 103, 462-468.	2.9	48

#	ARTICLE	IF	CITATIONS
73	Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 1025-1033.	0.8	134
74	Interfering with cell-survival signalling as a treatment strategy for prostate cancer. <i>BJU International</i> , 2006, 97, 1149-1153.	1.3	8
75	Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer. <i>BJU International</i> , 2005, 96, 640-646.	1.3	8
76	Unilateral testicular mass in man with chronic myelomonocytic leukemia: Unusual presentation of chronic myelomonocytic leukemia sequela. <i>Urology</i> , 2005, 65, 1001.	0.5	6
77	Inorganic Selenium Retards Progression of Experimental Hormone Refractory Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, 907-910.	0.2	90